Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivelestat sodium for ARDS associated with brain injury (observational cohort)
ChiCTR2500108494Phase 4Not yet recruiting
- Sponsor
- Mianyang Central Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sivelestat in acute respiratory distress syndrome (ARDS) and traumatic brain injury (TBI) (2 arms), sponsored by Mianyang Central Hospital. Primary endpoint: Oxygenation index PaO2/FiO2. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
sivelestat
03
Conditions
acute respiratory distress syndrome (ARDS)traumatic brain injury (TBI)
Beyond the preview
Go deeper on ChiCTR2500108494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108494.